Key Highlights

  • Shares are trading at $227.94 in pre-market activity, down 6.92% from Monday's close of $244.88.
  • Peer LabCorp also fell on news that CMS Medicare lab payment cuts are weighing on the diagnostics industry broadly.
  • The decline comes just a day after Truist and Baird both raised their price targets on the stock to $260.
  • The company's 2026 guidance calls for roughly 8% Revenue growth and more than 13% Earnings growth.

CMS Payment Cut Concerns Trigger a Sharp Pullback

Quest Diagnostics (NYSE:DGX) shares slid sharply in pre-market trading Tuesday, pulling back from Monday's close near $246, as peer LabCorp (NYSE:LH) also fell on news that new Medicare lab payment cuts from the Centers for Medicare & Medicaid Services are weighing on the diagnostics industry broadly. Quest Diagnostics is a Secaucus, New Jersey-based leading provider of diagnostic testing, information, and related services, generating the vast majority of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing.

Decline Contrasts With a Wave of Bullish Analyst Sentiment

The pre-market drop stands in contrast to bullish analyst sentiment just a day earlier, when Truist raised its price target on the stock to $260 and Baird lifted its target to $260 from $255, underscoring how the new Medicare reimbursement pressure is overshadowing otherwise constructive fundamentals.

Company Guidance and Recent Study Had Bolstered the Outlook

Those constructive fundamentals include 2026 guidance for roughly 8% revenue growth and more than 13% earnings growth, along with a widely covered study on tick-borne disease co-infections conducted with the University of North Carolina that had boosted the company's earnings outlook heading into this week.

Medicare Payment Policy Will Be the Key Swing Factor

Quest Diagnostics shares are under pressure as new Medicare reimbursement concerns outweigh otherwise bullish analyst sentiment and constructive company guidance for now. Further clarity on the scope and timing of the CMS payment cuts will likely determine whether the stock can recover from today's decline.